---

Asthma: GINA Classification and Long-Term Management of Uncontrolled Asthma

---

PART I: GINA CLASSIFICATION OF ASTHMA

A. Classification by Symptom Control (Current Control-Based)

• 0 "Yes" responses = Well-controlled asthma
• 1-2 "Yes" responses = Partly controlled asthma
• 3-4 "Yes" responses = Uncontrolled asthma

---

B. Classification by Severity (Retrospective - Based on Treatment Step Required)

---

C. Difficult-to-Treat vs. Severe Asthma (GINA 2024/2025 Distinction)

• Difficult-to-treat asthma: Uncontrolled despite Step 4-5 therapy, but due to modifiable factors (poor adherence, wrong inhaler technique, comorbidities, ongoing exposures). NOT true severe asthma.
• Severe asthma (ERS/ATS definition): Asthma that remains uncontrolled despite optimized high-dose ICS-LABA therapy, or that requires high-dose ICS-LABA/biologic therapy to prevent it from becoming uncontrolled.

1. Poor inhaler technique (up to 80% of community patients)
2. Poor medication adherence
3. Ongoing allergen/irritant exposure
4. Comorbidities: obesity, chronic rhinosinusitis, GERD, OSA
5. Psychological factors and socioeconomic issues

---

D. Risk Factors for Poor Asthma Outcomes (GINA)

• Uncontrolled symptoms
• Frequent SABA use (>2 times/week) or SABA overuse
• No ICS or inadequate ICS therapy
• Low lung function (FEV1 <60% predicted)
• History of severe exacerbation or near-fatal asthma
• Elevated FeNO and/or blood eosinophil count (BEC)
• Smoking or vaping
• Obesity, chronic rhinosinusitis, GERD, pregnancy
• Psychological and socioeconomic stress

---

PART II: LONG-TERM MANAGEMENT OF UNCONTROLLED ASTHMA

A. Goals of Management (GINA)

1. Achieve and maintain good symptom control
2. Minimize exacerbation risk, airflow obstruction, and medication side effects
3. Maintain normal activity levels
4. Ideally, achieve clinical remission (recently introduced concept - GINA 2022+)

---

B. GINA Stepwise Pharmacological Treatment (Adults and Adolescents >12 Years)

• Step 1: As-needed SABA (+ consider low-dose ICS whenever SABA used)
• Step 2: Low-dose ICS + as-needed SABA
• Steps 3-5: Same as Track 1 controller options + as-needed SABA

---

C. Step-Up Decision in Uncontrolled Asthma

1. Incorrect diagnosis
2. Poor inhaler technique - check at every visit
3. Non-adherence to prescribed therapy
4. Ongoing triggers (allergens, NSAIDs, beta-blockers, smoking)
5. Comorbidities (rhinosinusitis, GERD, obesity, OSA, vocal cord dysfunction)

---

D. Management of Uncontrolled Asthma at Steps 4 and 5

• Escalate to medium-dose ICS-LABA if Step 3 fails
• Add-on options at Step 4:
  • Tiotropium (LAMA): Add-on bronchodilator for symptomatic patients on ICS-LABA; shown to improve FEV1 and reduce exacerbations
  • LTRA (montelukast): Modest benefit, especially with allergic rhinitis
  • Azithromycin 500 mg 3 times weekly: Shown to reduce exacerbations in both eosinophilic and non-eosinophilic phenotypes (particularly for non-T2 asthma)

• Mandatory referral to specialist/severe asthma clinic
• Perform phenotyping workup:
  • Blood eosinophil count (BEC)
  • Fractional exhaled NO (FeNO)
  • Total and specific IgE, skin prick tests
  • Sputum eosinophils (research settings)
  • Chest CT, lung function, bronchial provocation tests

---

E. Non-Pharmacological Management (All Steps)

1. Patient education - written asthma action plan (mandatory for all patients)
2. Allergen avoidance - identify and reduce exposure to triggers
3. Smoking cessation - smoking reduces ICS efficacy significantly
4. Weight reduction - obesity worsens asthma; bariatric intervention improves control
5. Physical activity - structured exercise/pulmonary rehabilitation (GINA 2024 adds systematic review evidence)
6. Allergen immunotherapy (AIT): Subcutaneous (SCIT) or sublingual (SLIT) for sensitized patients with allergic asthma and FEV1 >70%; SLIT for house dust mite-sensitized patients at Step 3-4
7. Breathing exercises (Buteyko, yoga): Improve symptoms and quality of life
8. Psychosocial support - anxiety/depression worsen asthma control

---

F. Biologic (Targeted) Therapies for Severe Uncontrolled Asthma (Step 5)

1. Anti-IgE: Omalizumab (Xolair)

• Target: Binds IgE, blocks FcεRI receptor on mast cells/basophils
• Indication: Moderate-severe allergic asthma; elevated total IgE (30-700 IU/mL); sensitized to perennial allergen
• Dose: SC injection every 2-4 weeks (dose based on weight and IgE level)
• Benefits: Reduces exacerbations, improves control, steroid-sparing effect
• Biomarkers predicting response: High FeNO, high serum eosinophils, elevated periostin
• Note: Rare anaphylaxis risk; requires 3-4 month trial to assess response

2. Anti-IL-5: Mepolizumab (Nucala)

• Target: Blocks IL-5 cytokine (prevents eosinophil maturation/survival)
• Indication: Severe eosinophilic asthma; BEC ≥300/μL (or ≥150/μL with frequent exacerbations)
• Dose: 100 mg SC every 4 weeks
• Benefits: Reduces exacerbations, significant OCS-sparing effect

3. Anti-IL-5: Reslizumab (Cinqair)

• Target: Blocks IL-5 (IV route - potential drawback)
• Indication: BEC ≥400/μL; may be tried in partial/non-responders to mepolizumab (higher doses achievable)
• Dose: IV infusion every 4 weeks

4. Anti-IL-5Rα: Benralizumab (Fasenra)

• Target: Targets IL-5 receptor α - induces ADCC-mediated eosinophil apoptosis (rapid eosinophil depletion)
• Indication: Severe eosinophilic asthma; BEC ≥300/μL
• Dose: 30 mg SC every 4 weeks x3 doses, then every 8 weeks
• Advantage: More rapid action; IV benralizumab as single dose post-exacerbation reduces subsequent attacks
• May benefit patients with both eosinophilic and milder disease

5. Anti-IL-4Rα: Dupilumab (Dupixent)

• Target: Blocks shared IL-4/IL-13 receptor (IL-4Rα) - blocks both IL-4 and IL-13 signaling
• Indication: Moderate-severe uncontrolled asthma with type 2 inflammation
• Dose: 200-300 mg SC every 2 weeks
• Biomarker: FeNO is the best biomarker; BEC less predictive than for anti-IL-5
• Advantages: Also treats atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis - useful for "type 2 comorbidity" patients
• GINA 2025: FeNO ≥25 ppb (on medium-dose ICS) or ≥20 ppb (on high-dose ICS) is indicative of T2 inflammation

6. Anti-TSLP: Tezepelumab (Tezspire) - RECENT ADVANCE

• Target: Thymic stromal lymphopoietin (TSLP) - an "upstream" epithelial cytokine
• Mechanism: Blocks the initiating signal for ALL types of Type 2 inflammation (and possibly Type 1/Type 17)
• Indication: Severe uncontrolled asthma - unique: works regardless of eosinophil count (effective even in non-eosinophilic asthma)
• Benefits: Reduces exacerbations, FeNO, BEC, IgE; effective across all phenotypes
• GINA 2024/2025: Recommended at Step 5 as add-on therapy
• This represents a paradigm shift - the first biologic effective in non-T2 asthma

---

G. Summary Table: Biologic Selection by Phenotype

---

H. Add-on and Adjunct Therapies

• Triple therapy (ICS/LABA/LAMA): A 2024 umbrella review (PMID: 38864834) confirms ICS+LABA+LAMA reduces exacerbation risk in uncontrolled asthma
• Low-dose oral corticosteroids (OCS): Step 5 last resort; minimized due to systemic side effects (osteoporosis, diabetes, cataracts, adrenal suppression). Always attempt OCS-sparing strategies first.
• Bronchial thermoplasty: Endoscopic procedure that applies radiofrequency energy to airway smooth muscle, reducing airway hyperresponsiveness; FDA-approved for severe asthma in adults (≥18 years) not controlled on high-dose ICS-LABA; benefits persist >5 years but patient selection is crucial

---

PART III: RECENT ADVANCES (2023-2025)

1. GINA 2025 - ORACLE2 Study (PMID: 40215991 - Lancet Resp Med, 2025): Patient-level meta-analysis of 22 RCTs confirming that multiple factors (including T2 biomarkers - FeNO, BEC) should guide exacerbation risk assessment, not just symptom control scores
2. Tezepelumab approval: The first biologic effective across all asthma phenotypes (T2 and non-T2), addressing the unmet need in neutrophilic/non-eosinophilic severe asthma
3. Itepekimab (anti-IL-33): Phase 3 trials ongoing; targets IL-33 (another upstream epithelial alarmin); shows promise especially in ex-smokers with asthma/COPD overlap
4. FeNO and BEC biomarker redefinition (GINA 2025):
   • High BEC = ≥300/μL (typical T2 biologic threshold in severe asthma)
   • High FeNO (ICS-naive) = >50 ppb; on medium-dose ICS = ≥25 ppb; on high-dose ICS = ≥20 ppb
5. SABA overuse and harm (PMID: 40491263, 2025 meta-analysis): Confirmed that SABA overuse is independently associated with exacerbations, hospitalizations, and mortality - reinforcing GINA's move to ICS-formoterol reliever at all steps
6. Pulmonary rehabilitation: GINA 2024 now formally endorses structured pulmonary rehabilitation based on new systematic review/meta-analysis evidence
7. Clinical remission as a treatment goal: GINA introduced "clinical remission" as an achievable goal for severe asthma patients on biologic therapy (defined as no symptoms, no exacerbations, stable lung function)
8. Fluticasone furoate reclassification (GINA 2025): 100 mcg FF reclassified as low-medium dose, 200 mcg as medium-high dose, to avoid ambiguity when used in ICS-LABA combinations
9. Digital health/mHealth: GINA 2025 now includes guidance on using mHealth apps, while noting app inconsistency with current guidelines (PMID: 38198204)

---

PART IV: MONITORING AND STEPPING DOWN

• Reassess control every 2-3 months
• If well controlled for 3 months or more, consider stepping down (reduce ICS dose by ~25-50%)
• Stepping down should be done gradually, not abruptly
• If control lost on stepping down - confirm severe asthma diagnosis; restore previous dose
• Measure lung function (spirometry) periodically - FEV1 <70% predicted at presentation warrants step-up

---

EXAMINER'S SUMMARY POINTS

---

• Murray & Nadel's Textbook of Respiratory Medicine, Chapter 62 (Tables 62.1, 62.2, Fig 62.3)
• Fishman's Pulmonary Diseases and Disorders, Sections on Biologics
• GINA 2024 Strategy Report (ginasthma.org)
• GINA 2025 Update (ginasthma.org, November 2025)
• PMID: 40215991 (ORACLE2 meta-analysis, Lancet Resp Med 2025)
• PMID: 40491263 (SABA overuse meta-analysis, Allergy 2025)
• PMID: 38864834 (ICS/LABA/LAMA umbrella review 2024)